Novartis: Gilead licenses three preclinical stage programs

(CercleFinance.com) - U.
S. biotechnology company Gilead Sciences said on Friday that it has licensed three preclinical antiviral programs from Novartis, including agents to treat influenza and herpes.

Under the deal, Gilead will acquire exclusive global rights to develop and commercialise the molecules for an undisclosed upfront payment.

The Swiss drugmaker will also be eligible to receive up to an additional 291 million dollars in potential milestone payments, commercial milestones, and royalties, Gilead said.

Gilead's antiviral portfolio already includes medicines for the treatment of HIV, hepatitis B and hepatitis C, as well as influenza infection.

Copyright (c) 2019 CercleFinance.com. All rights reserved.